Two Sigma Advisers’s Pacira BioSciences PCRX Stock Holding History

Two Sigma Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-94,800	Closed	-$2.45M	–	1547
2025 Q4	$2.45M	Buy	94,800 +30,100	+47%	+$716K	﹤0.01%	1095
2025 Q3	$1.67M	Buy	64,700 +26,400	+69%	+$648K	﹤0.01%	1216
2025 Q2	$915K	Buy	38,300 +300	+0.8%	+$7.56K	﹤0.01%	1485
2025 Q1	$944K	Sell	38,000 -4,300	-10%	-$103K	﹤0.01%	1496
2024 Q4	$797K	Buy	+42,300	New	+$743K	﹤0.01%	1565
2024 Q3	–	Sell	-27,700	Closed	-$792K	–	2463
2024 Q2	$792K	Sell	27,700 -63,500	-70%	-$1.81M	﹤0.01%	1672
2024 Q1	$2.66M	Buy	91,200 +9,500	+12%	+$292K	0.01%	1072
2023 Q4	$2.76M	Sell	81,700 -36,000	-31%	-$1.05M	0.01%	1107
2023 Q3	$3.61M	Buy	117,700 +44,100	+60%	+$1.59M	0.01%	896
2023 Q2	$2.95M	Buy	73,600 +60,700	+471%	+$2.51M	0.01%	1001
2023 Q1	$526K	Buy	+12,900	New	+$513K	﹤0.01%	1928
2022 Q2	–	Sell	-16,776	Closed	-$1.28M	–	2828
2022 Q1	$1.28M	Sell	16,776 -61,200	-78%	-$4.08M	﹤0.01%	1497
2021 Q4	$4.69M	Sell	77,976 -127,700	-62%	-$7.04M	0.01%	797
2021 Q3	$11.5M	Sell	205,676 -151,600	-42%	-$8.74M	0.03%	473
2021 Q2	$21.7M	Buy	357,276 +303,700	+567%	+$19.2M	0.06%	312
2021 Q1	$3.75M	Buy	53,576 +26,800	+100%	+$1.91M	0.01%	979
2020 Q4	$1.6M	Buy	26,776 +2,100	+9%	+$123K	﹤0.01%	1369
2020 Q3	$1.48M	Buy	+24,676	New	+$1.43M	﹤0.01%	1314
2020 Q2	–	Sell	-8,276	Closed	-$277K	–	2582
2020 Q1	$277K	Sell	8,276 -47,800	-85%	-$1.99M	﹤0.01%	2045
2019 Q4	$2.54M	Sell	56,076 -6,400	-10%	-$272K	0.01%	1116
2019 Q3	$2.38M	Sell	62,476 -223,500	-78%	-$8.92M	0.01%	1047
2019 Q2	$12.4M	Buy	285,976 +46,200	+19%	+$1.96M	0.03%	530
2019 Q1	$9.13M	Sell	239,776 -30,600	-11%	-$1.19M	0.02%	637
2018 Q4	$11.6M	Buy	270,376 +117,500	+77%	+$5.48M	0.03%	520
2018 Q3	$7.51M	Buy	+152,876	New	+$6.61M	0.02%	668
2018 Q1	–	Sell	-221,076	Closed	-$10.1M	–	2392
2017 Q4	$10.1M	Buy	221,076 +199,376	+919%	+$7.9M	0.03%	605
2017 Q3	$815K	Sell	21,700 -30,476	-58%	-$1.23M	﹤0.01%	1554
2017 Q2	$2.49M	Buy	52,176 +37,800	+263%	+$1.75M	0.01%	1095
2017 Q1	$656K	Sell	14,376 -5,024	-26%	-$217K	﹤0.01%	1775
2016 Q4	$627K	Buy	19,400 +5,500	+40%	+$184K	﹤0.01%	1754
2016 Q3	$476K	Buy	13,900 +7,800	+128%	+$306K	﹤0.01%	1705
2016 Q2	$206K	Buy	+6,100	New	+$300K	﹤0.01%	1852
2016 Q1	–	Sell	-4,300	Closed	-$330K	–	2110
2015 Q4	$330K	Buy	+4,300	New	+$243K	﹤0.01%	1487
2014 Q4	–	Sell	-69,176	Closed	-$6.71M	–	2691
2014 Q3	$6.71M	Buy	69,176 +47,400	+218%	+$4.61M	0.05%	397
2014 Q2	$2M	Buy	21,776 +17,200	+376%	+$1.31M	0.02%	818
2014 Q1	$320K	Buy	+4,576	New	+$311K	﹤0.01%	1833

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers's PCRX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 94,800 shares — an estimated $2.45M sold.

Two Sigma Advisers first reported a position in PCRX in Q1 2014 and held it in 36 quarters. The position peaked at $21.7M in Q2 2021. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Two Sigma Advisers reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 94,800 Pacira BioSciences shares in Q1 2026, an estimated $2.45M.
Two Sigma Advisers first reported a position in Pacira BioSciences in Q1 2014 and held it in 36 quarters.
Two Sigma Advisers's Pacira BioSciences position peaked at $21.7M in Q2 2021.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.